The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma

Veterinary Journal

Volumn 195, Issue 3, 2013, Pages 319-324

  Sato, Masahiko ^a   Yamzaki, Jumpei ^a   Goto Koshino, Yuko ^a   Takahashi, Masashi ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dog; Lymphoma; Minimal residual disease; Prognosis; Real time PCR

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PREDNISOLONE; VINCRISTINE;

ALLELE; ANIMAL CARE; ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CELL COUNT; CLINICAL EVALUATION; CLINICAL PROTOCOL; DOG; DRUG INDUCED DISEASE; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE AMPLIFICATION; GENE SEQUENCE; HEMATOLOGIC DISEASE; IGH GENE; INDUCTION CHEMOTHERAPY; LYMPHOID CELL; LYMPHOMA CELL; MALE; MINIMAL RESIDUAL DISEASE; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; LYMPHOMA, B-CELL; MALE;

CANIS FAMILIARIS;

EID: 84875079539     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.07.013     Document Type: Article

References (27)

1. Bruggemann M., Raff T., Flohr T., Gokbuget N., Nakao M., Droese J., Luschen S., Pott C., Ritgen M., Scheuring U., Horst H.A., Thiel E., Hoelzer D., Bartram C.R., Kneba M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
2. Brugger W., Hirsch J., Grunebach F., Repp R., Brossart P., Vogel W., Kopp H.G., Manz M.G., Bitzer M., Schlimok G., Kaufmann M., Ganser A., Fehnle K., Gramatzki M., Kanz L. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study. Annals of Oncology 2004, 15:1691-1698.
3. Burnett R.C., Vernau W., Modiano J.F., Olver C.S., Moore P.F., Avery A.C. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Veterinary Pathology 2003, 40:32-41.
4. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., Felman P. Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human non-Hodgkin's lymphomas. Journal of Comparative Pathology 1997, 117:35-59.
5. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
6. Greenlee P.G., Filippa D.A., Quimby F.W., Patnaik A.K., Calvano S.E., Matus R.E., Kimmel M., Hurvitz A.I., Lieberman P.H. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990, 66:480-490.
7. Hosoya K., Kisseberth W.C., Lord L.K., Alvarez F.J., Lara-Garcia A., Kosarek C.E., London C.A., Couto C.G. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1355-1363.
8. Jacobs R.M., Messick J.B., Valli V.E. Tumors of the hemolymphatic system. Tumors of Domestic Animals 2002, State Press, Iowa, p. 138. Fourth Ed. D.J. Meuten (Ed.).
9. Kaiser H.E. Animal neoplasms: A systemic review. Neoplasms - Comparative Pathology in Animals, Plants and Man 1981, 747-812. Williams and Wilkins, Baltimore, MD, USA. H.E. Kaiser (Ed.).
10. Lana S.E., Jackson T.L., Burnett R.C., Morley P.S., Avery A.C. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. Journal of Veterinary Internal Medicine 2006, 20:329-334.
11. MacEwen E.G., Hayes A.A., Matus R.E., Kurzman I. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). Journal of the American Veterinary Medical Association 1987, 190:564-568.
12. Miller A.G., Morley P.S., Rao S., Avery A.C., Lana S.E., Olver C.S. Anemia is associated with decreased survival time in dogs with lymphoma. Journal of Veterinary Internal Medicine 2009, 23:116-122.
13. Miller W.H., Levine K., DeBlasio A., Frankel S.R., Dmitrovsky E., Warrell R.P. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993, 82:1689-1694.
14. Moore A.S., Cotter S.M., Rand W.M., Wood C.A., Williams L.E., London C.A., Frimberger A.E., L'Heureux D.A. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 2001, 15:348-354.
15. Pott C., Schrader C., Gesk S., Harder L., Tiemann M., Raff T., Bruggemann M., Ritgen M., Gahn B., Unterhalt M., Dreyling M., Hiddemann W., Siebert R., Dreger P., Kneba M. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
16. Rambaldi A., Lazzari M., Manzoni C., Carlotti E., Arcaini L., Baccarani M., Barbui T., Bernasconi C., Dastoli G., Fuga G., Gamba E., Gargantini L., Gattei V., Lauria F., Lazzarino M., Mandelli F., Morra E., Pulsoni A., Ribersani M., Rossi-Ferrini P.L., Rupolo M., Tura S., Zagonel V., Zaja F., Zinzani P., Reato G., Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002, 99:856-862.
17. Rassnick K.M., Moore A.S., Collister K.E., Northrup N.C., Kristal O., Chretin J.D., Bailey D.B. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. Journal of Veterinary Internal Medicine 2009, 23:317-322.
18. Sato M., Yamazaki J., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction. Journal of Veterinary Internal Medicine 2011, 25:285-291.
19. Simon D., Nolte I., Eberle N., Abbrederis N., Killich M., Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. Journal of Veterinary Internal Medicine 2006, 20:948-954.
20. Sorenmo K., Overley B., Krick E., Ferrara T., LaBlanc A., Shofer F. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology 2010, 8:196-208.
21. Tamura K., Yagihara H., Isotani M., Ono K., Washizu T., Bonkobara M. Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma. Veterinary Immunology and Immunopathology 2006, 110:163-167.
22. Vail, D.M., Michels, G.M., Khanna, C., Selting, K.A., London, C.A., Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 8, 28-37.
23. Valli V.E., Vernau W., de Lorimier L.P., Graham P.S., Moore P.F. Canine indolent nodular lymphoma. Veterinary Pathology 2006, 43:241-256.
24. Veterinary Co-operative Oncology Group, 2004. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2, 195-213.
25. Yamazaki J., Baba K., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K., Tsujimoto H. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Veterinary Immunology and Immunopathology 2008, 126:321-331.
26. Yamazaki J., Takahashi M., Setoguchi A., Fujino Y., Ohno K., Tsujimoto H. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: A proof-of-concept pilot study. Journal of Veterinary Internal Medicine 2010, 24:897-903.
27. Zhou J., Goldwasser M.A., Li A., Dahlberg S.E., Neuberg D., Wang H., Dalton V., McBride K.D., Sallan S.E., Silverman L.B., Gribben J.G. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007, 110:1607-1611.